Mycophenolate mofetil (free acid)
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 534859

CAS#: 128794-94-5 (free acid)

Description: Mycophenolate mofetil (free acid) is mycophenolic acid that is chemically altered by the addition of morpholinoethylester; selective and reversible inhibitor of inosine monophosphate dehydrogenase.


Chemical Structure

img
Mycophenolate mofetil (free acid)
CAS# 128794-94-5 (free acid)

Theoretical Analysis

MedKoo Cat#: 534859
Name: Mycophenolate mofetil (free acid)
CAS#: 128794-94-5 (free acid)
Chemical Formula: C23H31NO7
Exact Mass: 433.2101
Molecular Weight: 433.501
Elemental Analysis: C, 63.73; H, 7.21; N, 3.23; O, 25.83

Price and Availability

Size Price Availability Quantity
100.0mg USD 200.0 2 Weeks
1.0g USD 335.0 2 Weeks
Bulk inquiry

Related CAS #: 128794-94-5 (free acid)   116680-01-4 (HCl)  

Synonym: Mycophenolate mofetil (free acid)

IUPAC/Chemical Name: 2-Morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate

InChi Key: RTGDFNSFWBGLEC-SYZQJQIISA-N

InChi Code: InChI=1S/C23H31NO7/c1-15(5-7-19(25)30-13-10-24-8-11-29-12-9-24)4-6-17-21(26)20-18(14-31-23(20)27)16(2)22(17)28-3/h4,26H,5-14H2,1-3H3/b15-4+

SMILES Code: O=C(OCCN1CCOCC1)CC/C(C)=C/CC2=C(OC)C(C)=C3COC(C3=C2O)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 433.501 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Bullingham RE, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet. 1998 Jun;34(6):429-55. doi: 10.2165/00003088-199834060-00002. PMID: 9646007.

2: van Gelder T, Hesselink DA. Mycophenolate revisited. Transpl Int. 2015 May;28(5):508-15. doi: 10.1111/tri.12554. PMID: 25758949.

3: Zwerner J, Fiorentino D. Mycophenolate mofetil. Dermatol Ther. 2007 Jul- Aug;20(4):229-38. doi: 10.1111/j.1529-8019.2007.00136.x. PMID: 17970888.

4: Sievers TM, Rossi SJ, Ghobrial RM, Arriola E, Nishimura P, Kawano M, Holt CD. Mycophenolate mofetil. Pharmacotherapy. 1997 Nov-Dec;17(6):1178-97. PMID: 9399601.

5: Kaltenborn A, Schrem H. Mycophenolate mofetil in liver transplantation: a review. Ann Transplant. 2013 Dec 18;18:685-96. doi: 10.12659/AOT.889299. PMID: 24346057.

6: Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin Pharmacokinet. 2007;46(1):13-58. doi: 10.2165/00003088-200746010-00002. PMID: 17201457.

7: Orvis AK, Wesson SK, Breza TS Jr, Church AA, Mitchell CL, Watkins SW. Mycophenolate mofetil in dermatology. J Am Acad Dermatol. 2009 Feb;60(2):183-99; quiz 200-2. doi: 10.1016/j.jaad.2008.08.049. PMID: 19150270.

8: Lipsky JJ. Mycophenolate mofetil. Lancet. 1996 Nov 16;348(9038):1357-9. doi: 10.1016/S0140-6736(96)10310-X. PMID: 8918281.

9: Sepe V, Libetta C, Giuliano MG, Adamo G, Dal Canton A. Mycophenolate mofetil in primary glomerulopathies. Kidney Int. 2008 Jan;73(2):154-62. doi: 10.1038/sj.ki.5002653. Epub 2007 Nov 7. PMID: 17989649.

10: Ackermann AL, May ER, Frank LA. Use of mycophenolate mofetil to treat immune-mediated skin disease in 14 dogs - a retrospective evaluation. Vet Dermatol. 2017 Apr;28(2):195-e44. doi: 10.1111/vde.12400. Epub 2016 Dec 11. PMID: 27943548.

11: Villarroel MC, Hidalgo M, Jimeno A. Mycophenolate mofetil: An update. Drugs Today (Barc). 2009 Jul;45(7):521-32. doi: 10.1358/dot.2009.45.7.1384878. PMID: 19834629.

12: Moder KG. Mycophenolate mofetil: new applications for this immunosuppressant. Ann Allergy Asthma Immunol. 2003 Jan;90(1):15-19; quiz 20, 78. doi: 10.1016/S1081-1206(10)63607-1. PMID: 12546332.

13: Young M, Plosker GL. Mycophenolate mofetil: a pharmacoeconomic review of its use in solid organ transplantation. Pharmacoeconomics. 2002;20(10):675-713. doi: 10.2165/00019053-200220100-00004. PMID: 12162756.

14: Cahoon WD Jr, Kockler DR. Mycophenolate mofetil treatment of myasthenia gravis. Ann Pharmacother. 2006 Feb;40(2):295-8. doi: 10.1345/aph.1G501. Epub 2006 Jan 10. PMID: 16403848.

15: Walsh M, James M, Jayne D, Tonelli M, Manns BJ, Hemmelgarn BR. Mycophenolate mofetil for induction therapy of lupus nephritis: a systematic review and meta- analysis. Clin J Am Soc Nephrol. 2007 Sep;2(5):968-75. doi: 10.2215/CJN.01200307. Epub 2007 Aug 8. PMID: 17702723.

16: Nakaseko H, Iwata N, Yasuoka R, Kohagura T, Abe N, Kawabe S, Mori M. Pharmacokinetics of mycophenolate mofetil in juvenile patients with autoimmune diseases. Mod Rheumatol. 2019 Nov;29(6):1002-1006. doi: 10.1080/14397595.2018.1532785. Epub 2019 Jan 3. PMID: 30289014.

17: Eskin-Schwartz M, David M, Mimouni D. Mycophenolate mofetil for the management of autoimmune bullous diseases. Immunol Allergy Clin North Am. 2012 May;32(2):309-15, vii. doi: 10.1016/j.iac.2012.04.010. Epub 2012 Apr 18. PMID: 22560143.

18: Eskin-Schwartz M, David M, Mimouni D. Mycophenolate mofetil for the management of autoimmune bullous diseases. Dermatol Clin. 2011 Oct;29(4):555-9. doi: 10.1016/j.det.2011.06.012. Epub 2011 Aug 6. PMID: 21924997.

19: Geilen CC, Orfanos-Boeckel H, Offermann G, Orfanos CE. Mycophenolatmofetil: Ein neues Immunsuppressivum in der Dermatologie und seine Einsatzmöglichkeiten [Mycophenolate mofetil: a new immunosuppressive drug in dermatology and its possible uses]. Hautarzt. 2000 Feb;51(2):63-9. German. doi: 10.1007/s001050050013. PMID: 10743574.

20: Hood KA, Zarembski DG. Mycophenolate mofetil: a unique immunosuppressive agent. Am J Health Syst Pharm. 1997 Feb 1;54(3):285-94. doi: 10.1093/ajhp/54.3.285. PMID: 9028422.